As shown in Figure 6, the overall total mutation rate (missense mutations, truncations, amplifications, and deletions) of PLOD1/2/3 in ccRCC patients was 3.1%, with individual rates for PLOD1, PLOD2, and PLOD3 of 0.4%, 1.2%, and 1.5%, respectively (Figure 6A). This evidence concerns the gene PLOD2 and nonpapillary renal cell carcinoma.